126 related articles for article (PubMed ID: 22068465)
1. Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma.
Hinotsu S; Kawai K; Ozono S; Tsushima T; Tokuda N; Nomata K; Naito S; Akaza H
Int J Clin Oncol; 2013 Feb; 18(1):68-74. PubMed ID: 22068465
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
[TBL] [Abstract][Full Text] [Related]
3. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.
Pizzocaro G; Piva L; Colavita M; Ferri S; Artusi R; Boracchi P; Parmiani G; Marubini E
J Clin Oncol; 2001 Jan; 19(2):425-31. PubMed ID: 11208835
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.
Shinohara N; Kumagai A; Kanagawa K; Maruyama S; Abe T; Sazawa A; Nonomura K
Jpn J Clin Oncol; 2009 Nov; 39(11):720-6. PubMed ID: 19684042
[TBL] [Abstract][Full Text] [Related]
7. Postoperative influence of interferon alpha on patients with renal cell carcinoma.
Levakov I; Vojinov S; Jeremić D; Dozić J; Vignjević O
Med Pregl; 2011; 64(3-4):173-7. PubMed ID: 21905595
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Negrier S; Perol D; Ravaud A; Chevreau C; Bay JO; Delva R; Sevin E; Caty A; Escudier B;
Cancer; 2007 Dec; 110(11):2468-77. PubMed ID: 17932908
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson J; Gurney H; Selby P; Figlin R; Negrier S; Ernst S; Siebels M; Ginsberg M; Rittweger K; Hooftman L
Ann Oncol; 2002 Nov; 13(11):1799-805. PubMed ID: 12419754
[TBL] [Abstract][Full Text] [Related]
17. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
Tannir NM; Cohen L; Wang X; Thall P; Mathew PF; Jonasch E; Siefker-Radtke A; Pagliaro LC; Ng CS; Logothetis C
Cancer; 2006 Nov; 107(9):2254-61. PubMed ID: 17029276
[TBL] [Abstract][Full Text] [Related]
18. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Blute ML; Amling CL; Bryant SC; Zincke H
Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
